Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Septerna, Inc. (SEPN : NSDQ)

• Company Description    Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 75

• Price / Volume Information    Yesterday's Closing Price: $11.68 Daily Weekly Monthly 20 Day Moving Average: 418,545 shares Shares Outstanding: 44.56 (millions) Market Capitalization: $520.44 (millions) Beta: 52 Week High: $28.99 52 Week Low: $4.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.20% 8.00% 12 Week 97.97% 66.52% Year To Date -49.00% -52.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 250 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-338-3533 fax: - renee@thrustsc.com https://septerna.com

• General Corporate Information    Officers Jeffrey Finer - Chief Executive Officer; President and Director Jeffrey Tong - Chairman and Director Gil M. Labrucherie - Chief Financial Officer Abraham Bassan - Director Bernard Coulie - Director Peer Information Septerna, Inc. (CORR.) Septerna, Inc. (RSPI) Septerna, Inc. (CGXP) Septerna, Inc. (BGEN) Septerna, Inc. (GTBP) Septerna, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81734D104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/21/25 Share - Related Items Shares Outstanding: 44.56 Most Recent Split Date: (:1) Beta: Market Capitalization: $520.44 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.12 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.30 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 23.44% Sales Growth vs. Year Ago Period: -30.91% vs. Previous Quarter: 3.30% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 32.19 12/31/24 - 27.77 Quick Ratio 06/30/25 - - 03/31/25 - 32.19 12/31/24 - 27.77 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -6,725.21 Book Value 06/30/25 - - 03/31/25 - 8.99 12/31/24 - 9.46 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©